Resumo

ZIRPOLI, María Mercedes; ADAMCZUK, Yolanda  e  DUBOSCQ, Cristina. Quality requirements in hemostasis: Biological variability versus the state of art. Acta bioquím. clín. latinoam. [online]. 2016, vol.50, n.2, pp.303-308. ISSN 0325-2957.

The aim of this work was to compare the quality requirements of biological variability (BV) with the state of the art (SA) in eight hemostasis analytes. SA was determined by calculating the weighted average coefficient of variation (CVwa) of at least 6 external evaluations: RIQAS (ET1) and CAP (ET2). Data acceptable total error (TEa) for minimum and desirable biological variability (VBm y VBd) was calculated from the coefficient of variation (CV) within-subject and between subject www.westgard.com reported. The following was the data : Prothrombin time ( PT second): ETVBm 7.9%, ETVBd 5.3%, ET1 19%, ET2 13%; Activated partial thromboplastin time (second APTT): ETVBm 6.7%, ETVBd 4.5%, ET1 23%, ET2 11%; INR: ETVBm 7.9%, ETVBd 5.3%, ET1 20%, ET2 16%; Fibrinogen: ETVBm 20.4% ETVBd 13.6% ET1 20%, ET2 16%, FVIII: ETVBm 13.3%, ETVBd 8.9%, ET1 30%, ET2 45% ; FVII: ETVBm 16.1%, ETVBd 10.7%, ET1 31%, ET2 42%; chromogenic Protein C (PCc): ETVBm 28%, ETVBd 18.7%, ET1 36%, ET2 25%; free Protein S (PSf): ETVBm 31.1% ETVBd 20.7%, ET1 18%, ET2 28%; chromogenic Antithrombin (ATc): ETVBm 12.5%, ETVBd8.9%, ET1 18%, ET2 28%.The only analytes that meet the VBm or VBd quality requirement are fibrinogen, PC and PS. While each laboratory can decide the quality specifications it wants to apply, the issue to be discussed is: “what is the desirable quality requirement for clinical usefulness of these tests?”.

Palavras-chave : Biological variability; Quality requirements; State of the art; Hemostasis analytes; Acceptable total error; Current status of the methodology.

        · resumo em Português | Espanhol     · texto em Espanhol     · Espanhol ( pdf )